enGene (ENGN) Stock Price, News & Analysis

Company Overview

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Key Stats

• Today's Range: $6.70 to $7.85
• 50-Day Range: $5.26 to $9.50
• 52-Week Range: $4.94 to $43.00
• Volume: 117,338 shs
• Average Volume: 86,527 shs
• Market Capitalization: $321.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.67
• Consensus Rating: Buy

enGene Stock Analysis - MarketRank™

enGene scored higher than 53% of companies evaluated by MarketBeat, and ranked 573rd out of 1,017 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

enGene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

enGene has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for enGene are expected to decrease in the coming year, from ($1.49) to ($1.70) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of enGene is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of enGene is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

enGene has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.97% of the float of enGene has been sold short.

Short Interest Ratio / Days to Cover

enGene has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in enGene has recently increased by 31.26%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

enGene does not currently pay a dividend.

Dividend Growth

enGene does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.97% of the float of enGene has been sold short.

Short Interest Ratio / Days to Cover

enGene has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in enGene has recently increased by 31.26%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.03

News Sentiment

enGene has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 33 news articles for enGene this week, compared to 23 articles on an average week.

MarketBeat Follows

1 people have added enGene to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, enGene insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.70% of the stock of enGene is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

64.16% of the stock of enGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ENGN Stock Analysis - Frequently Asked Questions

How have ENGN shares performed this year?

enGene's stock was trading at $9.23 at the beginning of the year. Since then, ENGN shares have decreased by 21.2% and is now trading at $7.27.
View the best growth stocks for 2024 here.

How were enGene's earnings last quarter?

enGene Holdings Inc. (NASDAQ:ENGN) posted its quarterly earnings results on Tuesday, September, 10th. The company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.05.

Who are enGene's major shareholders?

enGene's top institutional investors include Blue Owl Capital Holdings LP (5.55%), Logos Global Management LP (2.72%), Perceptive Advisors LLC (1.81%) and Marshall Wace LLP (1.73%).
View institutional ownership trends.

How do I buy shares of enGene?

Shares of ENGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 9/10/2024
• Today: 9/19/2024
• Fiscal Year End: 10/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ENGN
• Previous Symbol: NASDAQ:ENGN
• CUSIP: N/A
• CIK: 1980845
• Web: www.engene.com
• Phone: 302-273-0765
• Fax: N/A
• Employees: 31
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $33.67
• High Stock Price Target: $40.00
• Low Stock Price Target: $30.00
• Potential Upside/Downside: +363.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.66)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-99,920,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -66.38%
• Return on Assets: -56.00%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 19.52
• Quick Ratio: 42.80

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $4.91 per share
• Price / Cash Flow: 1.48
• Book Value: $5.22 per share
• Price / Book: 1.39

Miscellaneous

• Outstanding Shares: 44,166,000
• Free Float: 38,115,000
• Market Cap: $321.09 million
• Optionable: N/A
• Beta: -0.67